An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia.
about
RRD-251 enhances all-trans retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells.Developing drugs that target the Wnt pathway: recent approaches in cancer and neurodegenerative diseases.Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer.In vitro and in vivo anti-tumor and anti-inflammatory capabilities of the novel GSK3 and CKD9 inhibitor ABC1183.Comparative High-Resolution Transcriptome Sequencing of Lymphoma Cell Lines and de novo Lymphomas Reveals Cell-Line-Specific Pathway Dysregulation.Aberrant expression of glycogen synthase kinase-3β in human breast and head and neck cancer
P2860
An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
An open-label phase 2 study of ...... patients with acute leukemia.
@ast
An open-label phase 2 study of ...... patients with acute leukemia.
@en
type
label
An open-label phase 2 study of ...... patients with acute leukemia.
@ast
An open-label phase 2 study of ...... patients with acute leukemia.
@en
prefLabel
An open-label phase 2 study of ...... patients with acute leukemia.
@ast
An open-label phase 2 study of ...... patients with acute leukemia.
@en
P2093
P2860
P1433
P1476
An open-label phase 2 study of ...... patients with acute leukemia.
@en
P2093
David A Rizzieri
Kay Hoong Chow
Kimberley Jackson
Leslie Brail
Lisette Moonan
Olatoyosi Odenike
Sarah Cooley
Xuejing Wang
P2860
P304
P356
10.3109/10428194.2015.1122781
P577
2016-01-06T00:00:00Z